پھانسی والے جیالے
سرفروشی کے انداز بدلے گئے تو دعوت قتل پر مقتل شہر میں
ڈال کر کوئی گردن میں طوق آ گیا لاد کر کوئی کاندھے پہ دار آ گیا
مارشل لاء کے دور میں پھانسی پانے والے پاکستان پیپلز پارٹی کے جیالے ۔مرزا ادریس بیگ شہید،ادریس طوطی شہید،عثمان غنی شہید،عبدلرزاق جھرنا شہید ،ایاز سموں شہید ،ناصر بلوچ شہید
Mufti Muhammad Taqi Usmani is one of the leading Deoband Hanafi Islamic Scholars living today from Pakistan. He is the son of late Molana Muhammad Shafi, the grand mufti of Pakistan. He is the brother of Islamic scholars Muhammad Rafi Usmani, Muhammad Wali Razi, Muhammad Razi Usmani as well as of Urdu poet Muhammad Zaki Kaifi. He is regarded as an expert in the fields of Hadith, Islamic Jurisprudence (Fiqh), Economics and Tasawwuf. He served as a judge on the Federal Shariat Court of Pakistan from 1980 to 1982 and the Shariat Appellate Bench of the Supreme Court of Pakistan between 1982 and 2002. He is generally known as one of the leading Shariah Scholars active in the field of Islamic finance. For more than a decade he has served as Chairman or Member of Shariah Supervisory boards of a dozen Islamic banks and prestigious financial institutions in various parts of the world. Allah Almighty has blessed him with the writing skill. He has written translations of the Holy Quran in both English and Urdu. He has been writing on various Islamic topics in Arabic, Urdu & English and is author of more than 70 books and numerous articles, published in a number of journals and magazines. In his books, Justice Taqi Usmani has discussed the solutions of individual, collective, social, political and economic problems in the light of Islamic principles. His books are very famous not only in Pakistan but also in India, Malaysia, Bangladesh and many other countries in the world. With this perspective, the present article deals with the introduction of important books of Mufti Muhammad Taqi Usmani.
Pioglitazone is an oral anti-diabetic agent which belongs to a class “thiazolidinediones”. It is used in the treatment of type 2 diabetes mellitus. It acts primarily by increasing peripheral sensitivity to insulin through binding to peroxisome proliferators activated receptor gamma. In recent years, due to variation in pharmacokinetic parameters under different environmental conditions, drug pharmacokinetics has received increasing attention. Therefore, the present study was designed to evaluate the biokinetics, renal clearance and effect on glycation level of pioglitazone in human beings under indigenous conditions. After through clinical examination healthy male volunteers (n = 24), female volunteers (n = 12) and diabetic patients (n = 8) were selected for the study. Each volunteer was given a therapeutic dose of 30 mg pioglitazone tablet orally. Patients were given a dose of 30 mg pioglitazone daily up to 12 weeks. In healthy volunteers scheduled plasma and urine samples were collected at different time intervals. Concentration of pioglitazone in plasma and urine samples was determined by validated high performance liquid chromatographic method. For the estimation of renal clearance of pioglitazone, the endogenous creatinine level was measured in plasma and urine samples spectrophotometrically using kit method based on Jaffe reaction. In plasma samples obtained from healthy volunteers and patients, amount of glucose was estimated by kit method, proteins by Biuret method and glycation level was measured by Thiobarbituric acid (TBA) method, spectrophotometerically. Both differences and similarities are present in the values of different calculated parameters and the values reported in the literature. After comparison minor sex differences were also found to be present in the values of different calculated parameters but statistically these differences were found to be non-significant. A single dose of pioglitazone (30 mg) has no effect on glucose concentration and glycation level in healthy male volunteers. Long term treatment of pioglitazone in diabetic patients, significantly decreased the glucose concentration and glycation level. This indicates that pioglitazone acts as an inhibitor of glycation.